Jacobs Levy Equity Management Inc. Has $5.08 Million Stock Holdings in USANA Health Sciences, Inc. $USNA

Key Points

• Jacobs Levy Equity Management Inc. increased its holdings in USANA Health Sciences by 46.2%, acquiring an additional 59,535 shares, bringing its total to 188,511 shares worth approximately $5.08 million.
• USANA Health Sciences stock rose 2.4%, trading at $30.85 with a market capitalization of $563.70 million and a P/E ratio of 17.14.
• Analysts have upgraded USANA Health Sciences from a "hold" to a "buy" rating, with a consensus target price of $36.00.

Jacobs Levy Equity Management Inc. increased its position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 46.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,511 shares of the company's stock after acquiring an additional 59,535 shares during the period. Jacobs Levy Equity Management Inc. owned about 1.01% of USANA Health Sciences worth $5,084,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of USNA. PNC Financial Services Group Inc. raised its holdings in shares of USANA Health Sciences by 339.6% during the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock worth $27,000 after acquiring an additional 771 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of USANA Health Sciences by 542.5% during the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock worth $31,000 after acquiring an additional 971 shares in the last quarter. Parallel Advisors LLC increased its position in USANA Health Sciences by 8,141.2% during the first quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock worth $38,000 after buying an additional 1,384 shares during the last quarter. AlphaQuest LLC increased its position in USANA Health Sciences by 300.9% during the first quarter. AlphaQuest LLC now owns 3,412 shares of the company's stock worth $92,000 after buying an additional 2,561 shares during the last quarter. Finally, US Bancorp DE increased its position in USANA Health Sciences by 13.1% during the first quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after buying an additional 535 shares during the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at USANA Health Sciences

In related news, insider David Mulham Mulham sold 3,515 shares of USANA Health Sciences stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the sale, the insider directly owned 9,260 shares of the company's stock, valued at $280,207.60. This trade represents a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilbert A. Fuller sold 1,058 shares of USANA Health Sciences stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $29.10, for a total value of $30,787.80. The disclosure for this sale can be found here. 0.63% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $36.00.

USANA Health Sciences Stock Performance

Shares of NYSE:USNA traded down $0.30 during midday trading on Friday, hitting $30.56. The company's stock had a trading volume of 129,872 shares, compared to its average volume of 172,132. The stock has a market capitalization of $558.33 million, a price-to-earnings ratio of 16.98, a PEG ratio of 0.96 and a beta of 0.64. The stock's 50 day simple moving average is $31.13 and its 200 day simple moving average is $29.56. USANA Health Sciences, Inc. has a fifty-two week low of $23.10 and a fifty-two week high of $41.83.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.20. The company had revenue of $235.85 million for the quarter, compared to the consensus estimate of $225.20 million. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. As a group, analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.